Liu Jian-Lun, Wei Wei, Tang Wei, Jiang Yi, Yang Hua-Wei, Li Jing-Tao, Zhou Xiao
Department of Breast Surgery, Cancer Hospital, Guangxi Medical University, Guangxi, China.
Asian Pac J Cancer Prev. 2012;13(7):3507-11. doi: 10.7314/apjcp.2012.13.7.3507.
The aim of this study was to investigate possible mechanisms of LOX gene effects on invasion and metastasis of breast cancer cells by RNA interference.
LOX-RNAi-LV was designed, synthesized, and then transfected into a breast cancer cell line (MDA-MB-231). Expression of LOX, MMP-2 and MMP-9 was determined by real-time PCR, and protein expression of LOX by Western blotting. Cell migration and invasiveness were assessed with Transwell chambers. A total of 111 cases of breast cancer tissues, cancer-adjacent normal breast tissues, and 20 cases of benign lesion tissues were assessed by immunohistochemistry.
Expression of LOX mRNA and protein was suppressed, and the expression of MMP-2 and MMP-9 was significantly lower in the RNAi group than the control group (P<0.05), after LOX-RNAi-LV was transfection into MDA-MB-231 cells. Migration and invasion abilities were obviously inhibited. The expression of LOX protein in breast cancer, cancer-adjacent normal breast tissues and benign breast tumor were 48.6% (54/111), 26.1% (29/111), 20.0% (4/20), respectively, associations being noted with clinical stage, lymph node metastasis, tumor size and ER, PR, HER2, but not age. LOX protein was positively correlated with MMP-2 and MMP-9.
LOX displayed an important role in invasion and metastasis of breast cancer by regulating MMP-2 and MMP-9 expression which probably exerted synergistic effects on the extracellular matrix (ECM).
本研究旨在通过RNA干扰探讨赖氨氧化酶(LOX)基因影响乳腺癌细胞侵袭和转移的可能机制。
设计、合成LOX-RNAi-LV,然后转染至乳腺癌细胞系(MDA-MB-231)。通过实时定量聚合酶链反应(real-time PCR)测定LOX、基质金属蛋白酶-2(MMP-2)和基质金属蛋白酶-9(MMP-9)的表达,通过蛋白质免疫印迹法检测LOX蛋白表达。使用Transwell小室评估细胞迁移和侵袭能力。通过免疫组织化学对111例乳腺癌组织、癌旁正常乳腺组织及20例良性病变组织进行评估。
将LOX-RNAi-LV转染至MDA-MB-231细胞后,RNA干扰组中LOX信使核糖核酸(mRNA)和蛋白表达受到抑制,MMP-2和MMP-9的表达明显低于对照组(P<0.05)。迁移和侵袭能力明显受到抑制。乳腺癌组织、癌旁正常乳腺组织及乳腺良性肿瘤中LOX蛋白的表达分别为48.6%(54/111)、26.1%(29/111)、20.0%(4/20),其与临床分期、淋巴结转移、肿瘤大小及雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER2)相关,但与年龄无关。LOX蛋白与MMP-2和MMP-9呈正相关。
LOX通过调节MMP-2和MMP-9的表达在乳腺癌的侵袭和转移中发挥重要作用,而MMP-2和MMP-9可能对细胞外基质(ECM)发挥协同作用。